FDA Approves Gazyva for Idiopathic Nephrotic Syndrome in Patients Aged 2 and Up
The FDA has approved Gazyva (obinutuzumab) to reduce relapse risk in idiopathic nephrotic syndrome for patients aged 2 and older, carrying boxed warnings for hepatitis B reactivation and PML.
The US Food and Drug Administration has approved Gazyva, known generically as obinutuzumab, for use in reducing the risk of relapse in patients with idiopathic nephrotic syndrome. The approval covers both pediatric and adult patients aged two years and older.
Idiopathic nephrotic syndrome is a kidney disorder marked by heavy protein loss in the urine, and relapses remain a central challenge in its long-term management. The new indication positions obinutuzumab as a treatment option aimed at extending the time patients spend free of relapse.
The agency flagged two serious safety concerns that accompany the drug. Gazyva carries a boxed warning — the FDA's most prominent caution — for hepatitis B reactivation and for progressive multifocal leukoencephalopathy, a rare but severe brain condition.
Boxed warnings are reserved for risks that may cause serious injury or death, and their presence signals that clinicians will need to weigh the therapy's benefits against these potential harms when selecting patients.
The decision widens the treatment landscape for a condition that affects both children and adults, though the label's restrictions underscore the need for careful monitoring during use.